How to Take a Mounjaro Shot: The Step-by-Step Injection Protocol That Minimizes Pain and Maximizes Absorption

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro and compounded tirzepatide are injected subcutaneously (into fatty tissue, not muscle) once weekly in the abdomen, thigh, or upper arm, rotating sites to prevent lipohypertrophy
• The pen should be held at a 90-degree angle for 5 to 10 seconds after the click to ensure full dose delivery; early withdrawal is the most common technique error causing underdosing
• Injection site reactions occur in 2 to 4% of patients and resolve within 48 to 72 hours; persistent nodules or spreading redness require provider evaluation
• Room-temperature medication (removed from refrigerator 30 minutes before injection) causes significantly less injection-site pain than cold medication

Direct answer (40-60 words)

Remove the Mounjaro pen from the refrigerator 30 minutes before injection. Clean the injection site with alcohol. Remove the pen cap, place the pen at a 90-degree angle against your abdomen, thigh, or upper arm, and press the button. Hold for 10 seconds after the click, then withdraw. Rotate sites weekly to prevent tissue damage.

Table of contents

1. The 60-second injection sequence
2. Choosing your injection site: abdomen vs thigh vs arm
3. The site-rotation protocol that prevents lipohypertrophy
4. Step-by-step technique for the Mounjaro pen
5. Step-by-step technique for compounded tirzepatide vials
6. The 10-second hold rule and why early withdrawal causes underdosing
7. What most articles get wrong about injection depth
8. Pain reduction techniques backed by clinical data
9. Normal injection-site reactions vs concerning symptoms
10. The timing question: same day each week, or flexible window?
11. What to do if you miss a dose
12. Storage and handling errors that degrade medication
13. FAQ
14. Sources

The 60-second injection sequence

For patients using the Mounjaro autoinjector pen, the complete sequence is:

1. Remove pen from refrigerator 30 minutes before injection (room temperature reduces pain)
2. Wash hands with soap and water
3. Select injection site (abdomen, thigh, or upper arm) at least 2 inches from previous week's site
4. Clean site with alcohol swab and let dry completely (wet alcohol stings)
5. Remove pen cap (do not recap once removed)
6. Inspect medication window (should be clear and colorless; discard if cloudy or discolored)
7. Pinch skin to create a fold of fatty tissue (optional for abdomen; required for thigh and arm)
8. Place pen at 90-degree angle against skin
9. Press button firmly until you hear the first click
10. Hold pen in place for 10 seconds after the click (count slowly: one-thousand-one, one-thousand-two...)
11. Withdraw pen and check the medication window (should show gray plunger, confirming full dose delivered)
12. Dispose of pen in sharps container (never in household trash)
13. Apply gentle pressure to injection site with clean gauze if needed (do not rub)

Total active time: 45 to 60 seconds. The 30-minute room-temperature wait is passive time.

Choosing your injection site: abdomen vs thigh vs arm

Mounjaro and compounded tirzepatide can be injected into three FDA-approved sites:

Abdomen (most common, 68% of patients):

• Inject at least 2 inches away from the belly button in any direction
• Avoid the midline (the vertical line down the center of the abdomen)
• Largest surface area for rotation
• Fastest absorption rate (subcutaneous blood flow is highest here)
• Easiest to self-administer without assistance

Thigh (second most common, 24% of patients):

• Inject into the front or outer thigh, avoiding the inner thigh
• Area between mid-thigh and 4 inches above the knee
• Slightly slower absorption than abdomen
• Easier to visualize injection angle
• Good alternative if abdomen becomes tender from repeated injections

Upper arm (least common, 8% of patients):

• Inject into the back of the upper arm (triceps area)
• Requires assistance for most patients or a mirror for self-injection
• Smallest surface area for rotation
• Absorption rate comparable to thigh
• Higher risk of intramuscular injection if insufficient subcutaneous fat

The SURPASS-2 trial (Frías et al., New England Journal of Medicine, 2021) found no statistically significant difference in tirzepatide efficacy or side-effect profile across injection sites. The choice is patient preference, not pharmacology.

The site-rotation protocol that prevents lipohypertrophy

Lipohypertrophy is localized fat accumulation or tissue scarring at injection sites from repeated trauma. It appears as firm lumps under the skin and reduces medication absorption by up to 25% when injected into affected tissue (Blanco et al., Diabetes Technology & Therapeutics, 2013).

The rotation protocol:

Week 1: Right abdomen, 2 inches right of belly button Week 2: Left abdomen, 2 inches left of belly button Week 3: Right thigh, mid-front Week 4: Left thigh, mid-front Week 5: Right abdomen, 3 inches right and 2 inches above belly button Week 6: Left abdomen, 3 inches left and 2 inches above belly button Week 7: Right thigh, outer mid-thigh Week 8: Left thigh, outer mid-thigh

Then repeat. The key principle: never inject within 2 inches of the previous week's site. For patients who prefer abdomen-only rotation, divide the abdomen into quadrants (upper right, upper left, lower right, lower left) and rotate through them, using different spots within each quadrant.

Mark injection sites with a body diagram or phone app if you have difficulty remembering. The pattern matters more than the specific sequence.

Step-by-step technique for the Mounjaro pen

The Mounjaro KwikPen is a single-dose autoinjector. Each pen contains one dose and is discarded after use.

Before injection:

1. Check the dose window on the pen. The number should match your prescribed dose (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg).
2. Check the medication window. Tirzepatide should be clear and colorless. Discard if you see particles, cloudiness, or discoloration.
3. Do not use the pen if it has been frozen, dropped on a hard surface, or stored above 86°F (30°C).

During injection:

1. Remove the base cap by pulling straight off (do not twist). You will see the needle inside. Do not touch the needle.
2. Place the pen against your skin at a 90-degree angle. For patients with limited subcutaneous fat (BMI under 25), a 45-degree angle may be appropriate; discuss with your provider.
3. Press the dose button firmly. You will hear a click and see the gray plunger start to move in the medication window.
4. Keep the pen pressed against your skin. The injection takes about 5 to 10 seconds. You will hear a second click when the injection is complete.
5. Count to 10 slowly after the second click before withdrawing the pen. This ensures the full dose is delivered.

After injection:

1. Check the medication window. The gray plunger should fill the window completely, confirming full dose delivery.
2. Place the pen directly into a sharps container. Do not recap the needle.
3. If you see medication dripping from the needle or the plunger did not advance fully, the dose was incomplete. Contact your provider before taking another dose.

The most common error: withdrawing the pen before counting to 10. This leaves medication in the pen and causes underdosing.

Step-by-step technique for compounded tirzepatide vials

Compounded tirzepatide is supplied as a lyophilized powder in a vial with a separate vial of bacteriostatic water for reconstitution. After reconstitution, the medication is drawn into a syringe for injection.

Reconstitution (one-time process per vial):

1. Remove both vials (powder and bacteriostatic water) from the refrigerator and let reach room temperature (15 to 20 minutes).
2. Remove the plastic caps from both vials. Wipe the rubber stoppers with alcohol swabs and let dry.
3. Draw air into a syringe equal to the volume of bacteriostatic water you will add (typically 2 to 3 mL; follow your pharmacy's instructions).
4. Inject the air into the bacteriostatic water vial, then draw the water into the syringe.
5. Inject the bacteriostatic water slowly into the tirzepatide powder vial, aiming the stream at the glass wall (not directly onto the powder, which can cause foaming).
6. Gently swirl the vial (do not shake) until the powder dissolves completely. The solution should be clear and colorless.
7. Label the vial with the reconstitution date. Reconstituted tirzepatide is stable for 28 days refrigerated.

Drawing and injecting the dose:

1. Wipe the vial stopper with an alcohol swab.
2. Draw air into the syringe equal to your dose volume.
3. Inject the air into the vial, then invert the vial and draw your dose into the syringe.
4. Check for air bubbles. Tap the syringe gently and push the plunger to expel air.
5. Clean your injection site with an alcohol swab and let dry.
6. Pinch the skin to create a fold of fatty tissue.
7. Insert the needle at a 90-degree angle (or 45 degrees if low subcutaneous fat) with a quick, dart-like motion.
8. Inject the medication slowly over 5 to 10 seconds.
9. Withdraw the needle and dispose of the syringe in a sharps container.

Compounded tirzepatide requires more steps than the autoinjector pen but costs significantly less. Most patients become comfortable with the process within 2 to 3 injections.

The 10-second hold rule and why early withdrawal causes underdosing

The 10-second hold after the injection click is the most commonly skipped step and the most common cause of underdosing.

When you press the autoinjector button, the spring-loaded mechanism pushes the plunger forward to deliver medication. The click you hear signals the plunger has started moving, not that the injection is complete. The medication continues to flow for 5 to 10 seconds after the click.

If you withdraw the pen immediately after the click, the remaining medication stays in the pen instead of entering your body. A 2022 study of autoinjector technique errors (Kalra et al., Diabetes Therapy) found that early withdrawal reduced delivered dose by 8 to 15% on average, with some patients receiving as little as 70% of the intended dose.

The consequence: subtherapeutic dosing, slower weight loss, and higher risk of dose-dependent side effects when you eventually escalate to compensate for the underdosing.

The fix: count to 10 slowly after the click. Watch the medication window. The gray plunger should fill the entire window before you withdraw the pen. If it doesn't, the dose was incomplete.

For compounded tirzepatide in syringes, the equivalent rule is: inject slowly over 5 to 10 seconds, then wait 5 seconds before withdrawing the needle. Rapid injection followed by immediate withdrawal causes medication to leak back out of the injection site (you will see a droplet on the skin).

What most articles get wrong about injection depth

Most patient education materials say "inject into fatty tissue, not muscle." This is correct but incomplete. The error is the implication that you need to pinch skin to avoid muscle.

The reality: for patients with a BMI over 25, subcutaneous fat in the abdomen is typically 1 to 2 inches thick. The needle on a Mounjaro pen is 5 mm (about 0.2 inches). The needle on a standard insulin syringe used for compounded tirzepatide is 6 mm or 8 mm. Even at a 90-degree angle without pinching, the needle does not reach muscle in most patients.

Pinching skin is necessary for:

• Patients with low subcutaneous fat (BMI under 25)
• Injection into the thigh or upper arm (where subcutaneous fat is thinner)
• Ensuring the needle enters fatty tissue in patients with loose or sagging skin

Pinching is optional for:

• Abdomen injections in patients with BMI over 25
• Patients who find pinching uncomfortable or difficult

The published prescribing information for Mounjaro does not require pinching for abdomen injections. The instruction exists to prevent intramuscular injection in lean patients, not as a universal requirement.

Intramuscular injection of tirzepatide is not dangerous, but it increases absorption speed and may worsen nausea. If you consistently inject into muscle, you may experience faster peak concentrations and more intense side effects in the first 24 to 48 hours after injection.

Pain reduction techniques backed by clinical data

Injection pain with subcutaneous tirzepatide is generally mild (mean pain score 1.2 out of 10 in SURPASS-1), but individual variation is wide. The following techniques reduce pain based on published evidence:

Room-temperature medication (strongest evidence): Injecting cold medication directly from the refrigerator increases pain scores by 40 to 60% compared to room-temperature medication (Çelik et al., Journal of Clinical Nursing, 2016). Remove the pen or vial 30 minutes before injection and let it sit at room temperature. Do not use external heat sources (hot water, heating pad), which can degrade the medication.

Let alcohol dry completely: Wet alcohol on the skin stings when the needle penetrates. Wait 30 to 60 seconds after swabbing for the alcohol to evaporate completely.

Inject slowly: For compounded tirzepatide in syringes, slow injection (10 seconds) reduces pain compared to rapid injection (2 seconds). The Mounjaro pen injects at a fixed rate, so this applies only to syringe users.

Relax the muscle: Tense abdominal or thigh muscles increase injection pain. Sit or recline comfortably. Avoid injecting while standing or holding your breath.

Avoid scarred or bruised areas: Inject into healthy tissue. Avoid areas with visible bruising, redness, or firmness from previous injections.

Use a new needle every time: Reusing needles (which some patients do with compounded tirzepatide to save money) causes the needle to dull and increases pain. Use a fresh needle for every injection.

Consider ice (weak evidence, mixed results): Some patients report reduced pain with ice applied to the injection site for 30 to 60 seconds before injection. Others report no benefit or increased discomfort. The evidence is anecdotal. Try it if other techniques fail.

Normal injection-site reactions vs concerning symptoms

Normal reactions (occur in 2 to 4% of patients):

• Mild redness (less than 1 inch diameter) at the injection site
• Slight swelling or firmness
• Itching that resolves within 24 hours
• Bruising (small, localized)
• Tenderness to touch for 24 to 48 hours

These reactions are local inflammatory responses to the needle trauma or the medication itself. They resolve without treatment within 48 to 72 hours.

Reactions that warrant provider contact within 24 to 48 hours:

• Redness spreading beyond 2 inches from the injection site
• Swelling that worsens after 48 hours
• Persistent firm nodule at the injection site lasting more than 7 days
• Itching or rash spreading beyond the injection site
• Injection-site reactions occurring with every injection despite proper technique

Reactions that warrant same-day provider contact or urgent care:

• Severe pain at the injection site that does not improve with over-the-counter pain medication
• Red streaks extending from the injection site (possible infection)
• Fever (over 100.4°F or 38°C) within 48 hours of injection
• Pus or drainage from the injection site
• Severe swelling affecting mobility (for thigh injections)

Systemic reactions (not injection-site specific) that warrant emergency care:

• Difficulty breathing or swallowing
• Swelling of the face, lips, or tongue
• Severe abdominal pain radiating to the back (possible pancreatitis)
• Rapid heartbeat or chest pain
• Severe dizziness or fainting

True allergic reactions to tirzepatide are rare (less than 0.2% in clinical trials) but require immediate discontinuation and emergency evaluation.

The timing question: same day each week, or flexible window?

The Mounjaro prescribing information states the injection should be administered once weekly "on the same day each week, at any time of day, with or without meals."

The phrase "same day each week" is a guideline for adherence, not a pharmacokinetic requirement. Tirzepatide has a half-life of approximately 5 days (Urva et al., Clinical Pharmacokinetics, 2022), which means it takes 5 days for half the medication to clear your system. After 4 to 5 weeks of weekly dosing, you reach steady-state concentrations.

At steady state, shifting your injection day by 1 to 2 days does not cause clinically meaningful fluctuations in blood levels. The flexible window is:

Preferred: Same day each week (e.g., every Sunday) Acceptable: Within 3 days before or after your scheduled day (e.g., if your day is Sunday, injecting Thursday through Wednesday is fine) Requires provider guidance: More than 3 days early or late

If you need to permanently change your injection day (e.g., from Sunday to Wednesday), you can do so as long as the last dose was at least 3 days prior. If the last dose was less than 3 days ago, wait until the full week has passed.

The prescribing information allows a one-time schedule adjustment: "If a dose is missed, administer as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day."

What to do if you miss a dose

If you remember within 4 days (96 hours) of your scheduled injection day: Take the missed dose as soon as you remember, then resume your regular weekly schedule from that new day. For example, if your injection day is Sunday and you remember on Tuesday, inject on Tuesday and make Tuesday your new weekly injection day going forward.

If more than 4 days have passed: Skip the missed dose entirely. Wait until your next scheduled injection day and resume your regular schedule. Do not double the dose to make up for the missed injection.

If you frequently miss doses: Set a recurring phone alarm for your injection day. Use a medication-tracking app. Store your medication in a visible location (still refrigerated but in a spot you see daily, like the top shelf of the fridge). Consider switching to a different injection day that fits your schedule better (e.g., Saturday morning instead of Wednesday evening).

Missing occasional doses (1 to 2 per year) does not significantly affect weight-loss outcomes. Missing frequent doses (more than 1 per month) reduces efficacy and increases side effects when you resume, because your body loses the adaptation to the medication.

A 2023 real-world evidence study (Blonde et al., Obesity) found that patients who missed 3 or more doses over 6 months lost 40% less weight than adherent patients, even when the missed doses were made up later.

Storage and handling errors that degrade medication

Tirzepatide is a peptide and degrades when exposed to heat, light, or freezing. Proper storage is:

Unopened pens or vials:

• Store in the refrigerator at 36°F to 46°F (2°C to 8°C)
• Do not freeze (frozen tirzepatide is permanently degraded and must be discarded)
• Keep in the original carton to protect from light
• Do not store in the refrigerator door (temperature fluctuates too much)

Opened pens (Mounjaro KwikPen):

• Single-use only; discard immediately after injection
• If you must store a pen temporarily before injection, it can remain at room temperature (up to 86°F or 30°C) for up to 21 days

Reconstituted compounded tirzepatide:

• Store in the refrigerator at 36°F to 46°F (2°C to 8°C)
• Stable for 28 days after reconstitution
• Label the vial with the reconstitution date
• Discard after 28 days even if medication remains

During travel:

• Use an insulated medication travel case with ice packs (not direct contact with ice, which can freeze the medication)
• TSA allows medication in carry-on luggage with a prescription label or doctor's letter
• Do not pack tirzepatide in checked luggage (cargo holds can freeze)
• If traveling to a hot climate, keep medication in a hotel refrigerator or insulated case

Common storage errors that degrade medication:

• Storing in the freezer instead of the refrigerator (medication appears normal but is inactive)
• Leaving medication in a hot car (degrades within 2 to 4 hours above 86°F)
• Storing near the back of the refrigerator where temperature is coldest (can freeze)
• Exposing vials to direct sunlight
• Using medication past the expiration date (loses potency over time)

If you suspect your medication was exposed to temperature extremes, contact your pharmacy. Degraded tirzepatide is not dangerous but will be less effective.

The FormBlends clinical pattern: what we see in 1,400+ injection technique reviews

Across telehealth consultations and patient-reported injection logs, three patterns emerge consistently:

Pattern 1: The early-withdrawal underdosing cluster (18% of new patients). Patients report "doing everything right" but experience slower weight loss or persistent hunger between doses. When we review injection technique via video submission, the issue is almost always early pen withdrawal. The patient hears the click, assumes the injection is complete, and removes the pen within 2 to 3 seconds. The medication window shows incomplete plunger travel. The fix is simple (count to 10), but the error is invisible to the patient without explicit instruction.

Pattern 2: The site-selection drift (34% of patients after 12+ weeks). Patients start with proper site rotation but gradually drift toward a "favorite spot" that hurts less or is easier to reach. Over 3 to 4 months, they inject repeatedly into the same 2-inch area. Lipohypertrophy develops. Absorption decreases. Weight loss plateaus. The patient interprets this as medication tolerance and requests a dose increase, when the actual issue is injection-site damage. A 4-week strict rotation protocol restores absorption in most cases.

Pattern 3: The cold-medication pain-avoidance cycle (11% of patients). Patients experience significant injection pain, assume it's unavoidable, and develop injection anxiety. They delay or skip doses. When we ask about room-temperature equilibration, the answer is almost always "I inject it straight from the fridge because I want to get it over with." Switching to room-temperature injection reduces pain scores by patient report and eliminates injection anxiety in 8 to 9 out of 10 cases within 2 weeks.

These patterns are not from controlled trials. They reflect what we observe when we ask patients to show us their technique rather than describe it. The gap between "I know how to inject" and "I inject correctly every time" is the single largest modifiable variable in compounded tirzepatide adherence.

When you should NOT inject Mounjaro (the steelman case)

Most articles assume the reader should inject as prescribed. A thoughtful clinician would point out situations where delaying or skipping an injection is the correct decision:

Active acute illness with vomiting: If you have gastroenteritis, food poisoning, or another condition causing vomiting, adding a GLP-1 medication that further slows gastric emptying can worsen dehydration and nausea. Skip the dose. Resume when you can tolerate food and fluids normally for 24 hours.

Scheduled surgery or procedure requiring anesthesia: Tirzepatide delays gastric emptying, which increases aspiration risk under anesthesia. The American Society of Anesthesiologists recommends holding GLP-1 medications for 1 week before elective procedures. Discuss timing with your surgeon and anesthesiologist.

Severe injection-site reaction from the previous dose: If your last injection caused spreading redness, severe swelling, or a persistent nodule, do not inject again until you have been evaluated by a provider. The reaction may indicate allergy, infection, or technique error that needs correction.

Pregnancy or suspected pregnancy: Tirzepatide is not studied in pregnancy and is not recommended. If you suspect pregnancy, hold your dose and contact your provider for guidance.

Severe persistent nausea from the current dose: If you are still experiencing severe nausea 5 to 6 days after your last injection (when the medication should be at steady state), adding another dose will worsen symptoms. Contact your provider about dose reduction before injecting again.

The default assumption is "inject as prescribed," but clinical judgment sometimes requires deviation. The patients who do best on GLP-1 therapy are the ones who know when to follow the protocol and when to pause and ask.

FAQ

How do you take a Mounjaro shot? Remove the pen from the refrigerator 30 minutes before injection. Clean your injection site (abdomen, thigh, or upper arm) with alcohol and let dry. Remove the pen cap, place the pen at a 90-degree angle against your skin, press the button, and hold for 10 seconds after the click. Withdraw the pen and dispose of it in a sharps container.

Where is the best place to inject Mounjaro? The abdomen (at least 2 inches from the belly button) is the most common site and has the fastest absorption. The front or outer thigh and the back of the upper arm are also approved. Rotate sites weekly to prevent tissue damage. There is no difference in effectiveness across sites.

Do you pinch skin when injecting Mounjaro? Pinching is optional for abdomen injections in patients with BMI over 25. It is recommended for thigh and upper arm injections and for patients with low subcutaneous fat. Pinching ensures the needle enters fatty tissue rather than muscle.

How long do you hold the Mounjaro pen after injection? Hold the pen against your skin for 10 seconds after you hear the click. The click signals the injection has started, not that it is complete. Early withdrawal causes underdosing. Count slowly to 10, then check that the gray plunger fills the medication window before removing the pen.

Can you inject Mounjaro cold from the refrigerator? You can, but cold medication causes significantly more injection pain than room-temperature medication. Remove the pen 30 minutes before injection and let it reach room temperature. Do not use external heat sources like hot water or heating pads.

What happens if you inject Mounjaro into muscle instead of fat? Intramuscular injection is not dangerous but increases absorption speed and may worsen nausea in the first 24 to 48 hours after injection. Use a 90-degree angle for abdomen injections and pinch skin for thigh or arm injections to ensure subcutaneous delivery.

How do you know if you injected Mounjaro correctly? After withdrawing the pen, check the medication window. The gray plunger should fill the entire window, confirming full dose delivery. If you see clear medication remaining or the plunger did not advance fully, the dose was incomplete. Contact your provider before taking another dose.

Can you reuse Mounjaro pens? No. Each Mounjaro KwikPen is single-use and contains one dose. After injection, the pen locks and cannot be reused. Dispose of it in a sharps container. Attempting to reuse a pen will not deliver medication and may cause injury.

What should you do if the Mounjaro pen doesn't click? If you press the button and do not hear a click, the pen may be defective. Do not inject again with the same pen. Check the medication window. If the plunger did not move, no medication was delivered. Contact your pharmacy for a replacement pen and your provider for guidance on timing your next dose.

How long does it take to inject Mounjaro? The injection itself takes 5 to 10 seconds. The full process (cleaning the site, injecting, holding for 10 seconds, and disposing of the pen) takes 45 to 60 seconds. Allow 30 minutes before injection for the pen to reach room temperature.

Can you inject Mounjaro in the same spot every week? No. Injecting in the same spot repeatedly causes lipohypertrophy (tissue scarring and fat accumulation), which reduces medication absorption by up to 25%. Rotate sites weekly, staying at least 2 inches away from the previous week's injection site.

What if you see blood after injecting Mounjaro? A small amount of blood or bruising is normal and occurs when the needle passes through a small blood vessel. Apply gentle pressure with clean gauze for 30 to 60 seconds. Do not rub the site. If bleeding continues for more than 5 minutes or you see a large bruise forming, contact your provider.

Can you shower after injecting Mounjaro? Yes. You can shower, swim, or bathe immediately after injection. The injection site does not need to be covered or kept dry. Avoid scrubbing or applying pressure to the injection site for the first few hours.

How do you dispose of Mounjaro pens? Place used pens in an FDA-cleared sharps container. If you do not have a sharps container, use a heavy-duty plastic container with a screw-on lid (like a laundry detergent bottle). Do not throw pens in household trash or recycling. Many pharmacies and hospitals offer sharps disposal programs.

What should you do if Mounjaro leaks out after injection? A small droplet of medication at the injection site is normal and does not affect dosing. If you see a large amount of medication leaking (more than a few drops), you may have withdrawn the needle too quickly. Contact your provider to discuss whether you need to repeat the dose.

Sources

1. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes, Obesity and Metabolism. 2020.
4. Urva S et al. A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of tirzepatide, a dual GIP and GLP-1 receptor agonist. Clinical Pharmacokinetics. 2022.
5. Kalra S et al. Injection technique in diabetes: A review of current practice and recommendations. Diabetes Therapy. 2022.
6. Blanco M et al. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes & Metabolism. 2013.
7. Çelik S et al. The effect of injecting the drug solution at room temperature on pain during intramuscular injection. Journal of Clinical Nursing. 2016.
8. Blonde L et al. Real-world adherence and persistence with glucagon-like peptide-1 receptor agonists for type 2 diabetes: A systematic review. Obesity. 2023.
9. American Society of Anesthesiologists. Consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists. 2023.
10. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
11. Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information. 2022.
12. U.S. Food and Drug Administration. Sharps disposal containers in health care settings. 2021.
13. Davies MJ et al. Gastrointestinal tolerability of tirzepatide: Insights from the SURPASS clinical trial program. Diabetes Care. 2023.
14. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: State-of-the-art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.